VBL Therapeutics falls on patient recruitment pause in ovarian cancer study

Notable Labs

15/06/2021 17:18

** Shares of the drug developer  VBLT.O  tumble 15.7% to
$2.25 - set to snap a two-day winning streak 
    ** Says it will temporarily pause recruitment of new U.S.
patients in its ongoing late-stage study testing VB-111, its
experimental treatment for platinum-resistant ovarian cancer
 urn:newsml:reuters.com:*:nGNX5PKH1x
    ** Expects a temporary shortage of study drug supply for the
U.S until new VB-111 batches are cleared by the Chemistry,
Manufacturing, and Controls (CMC) group
    ** Says to date, study has enrolled about 75% of the planned
400 patients and treatment will continue as usual for the
enrolled U.S. patients
    ** VBLT shares still trading above their record low price of
60 cents, reached on Dec. 21, 2018
    ** Stock up about 19% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))